Innovative mucus secretion stimulation for inflammation control in Inflammatory Bowel Disease

Introduction

Inflammatory bowel diseases (IBDs), such as Crohn’s disease and ulcerative colitis, are chronic, debilitating conditions affecting millions worldwide. There is currently no cure for IBD, only treatments aimed at inducing long-lasting remission.

Treatment Limitations

These treatment options act mainly by inhibiting the patient’s immune system, leaving patients immunocompromised, and come with a high annual direct cost. Even with advanced treatment, most IBD patients will require surgery during their lifetimes. Thus, more affordable treatment options that are not focused on immune suppression are needed.

Understanding IBD Etiology

While the etiology of IBDs is not clear, it is thought that the breakdown of gut barrier function is a major driver of chronic intestinal inflammation. Indeed, the penetrance of luminal microbes into the mucus layer that covers the intestinal epithelium is a hallmark of IBDs.

Impact of Microbial Penetrance

This penetrance and contact of microbes with the host’s immune system drives a pro-inflammatory response and prevents tissue healing.

Research Findings

While performing our ERC-funded research project, we found a way to induce excess intestinal mucus secretion in mice. We discovered that this excess mucus secretion protected mice from the development of colitis in a model of IBD.

Mechanism of Action

We also uncovered the mechanism that controls intestinal mucus secretion and discovered a cheap and reproducible way to pharmacologically induce excess mucus secretion using a bile acid.

Project Goals

Our goal is to determine whether pharmacologically inducing intestinal mucus production in preclinical mouse models of IBD can induce and sustain remission.

Methodology

The project's methodology encompasses preclinical trials utilizing three distinct mouse models to rigorously test the efficacy and safety of our innovation.

Market Analysis

A comprehensive market analysis, informed by stakeholders including healthcare professionals and patient advocacy groups, will guide the development process, ensuring the therapeutic approach meets the real-world needs of IBD patients.